➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Dow
Harvard Business School
Colorcon
Baxter

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

UVADEX Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Uvadex patents expire, and what generic alternatives are available?

Uvadex is a drug marketed by Mallinckrodt Hosp and is included in one NDA.

The generic ingredient in UVADEX is methoxsalen. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the methoxsalen profile page.

US ANDA Litigation and Generic Entry Outlook for Uvadex

A generic version of UVADEX was approved as methoxsalen by STRIDES PHARMA on June 5th, 2014.

  Start Trial

Drug patent expirations by year for UVADEX
Recent Clinical Trials for UVADEX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Clinical Trial Center North (CTC North GmbH & Co. KG)Phase 2
University Medical Center RegensburgPhase 2
Universitätsklinikum Hamburg-EppendorfPhase 2

See all UVADEX clinical trials

Pharmacology for UVADEX

US Patents and Regulatory Information for UVADEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinckrodt Hosp UVADEX methoxsalen INJECTABLE;INJECTION 020969-001 Feb 25, 1999 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for UVADEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mallinckrodt Hosp UVADEX methoxsalen INJECTABLE;INJECTION 020969-001 Feb 25, 1999   Start Trial   Start Trial
Mallinckrodt Hosp UVADEX methoxsalen INJECTABLE;INJECTION 020969-001 Feb 25, 1999   Start Trial   Start Trial
Mallinckrodt Hosp UVADEX methoxsalen INJECTABLE;INJECTION 020969-001 Feb 25, 1999   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for UVADEX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0177957 C990016 Netherlands   Start Trial PRODUCT NAME: BECAPLERMINUM; REGISTRATION NO/DATE: EU/1/99/101/001 19990329
0177957 99C0034 Belgium   Start Trial PRODUCT NAME: BECAPLERMIN; REGISTRATION NO/DATE: EU/1/99/101/001 19990329
0177957 SPC/GB99/023 United Kingdom   Start Trial PRODUCT NAME: BECAPLERMIN; REGISTERED: UK EU/1/99/101/001 19990329
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Moodys
Express Scripts
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.